I, non-adrenoceptor, imidazoline receptor agonists, such as moxonidine, increase urine flow rate and sodium excretion following infusion into the renal artery. The functions of these agonists in genetic and acquired models of hypertension have not been determined. 2 We therefore studied the renal effects of two known non-adrenoceptor, imidazoline receptor agonists, rilmenidine and moxonidine, in 1K-IC hypertensive and 1K-sham normotensive rats. Rilmenidine (0, 3, 10, 30 nmol kg-' min-') or moxonidine (0, 1, 3, 10 nmol kg-' min-') was infused directly into the renal artery (30 gauge needle) of 1K-sham normotensive and 1K-IC hypertensive rats. 3 In 1K-sham normotensive rats, rilmenidine and moxonidine produced dose related increases in urine flow rate, sodium excretion and osmolar clearance. Both rilmenidine and moxonidine failed to increase urine flow rate, sodium excretion and osmolar clearance in 1K-IC hypertensive rats to the same extent as in 1K-sham animals. At comparable doses, rilmenidine had no effect, while moxonidine (3 and 10 nmol kg-' min-') did result in a small increase in urine volume and osmolar clearance which was less than that observed in the 1K sham control animals. 4 These studies indicate that the renal effects of non-adrenoceptor, imidazoline receptor stimulation are diminished in 1K-IC hypertensive rats compared with 1K-sham normotensive rats. Whether this decrease in activity of the natriuretic non-adrenoceptor, imidazoline receptors contributes to the increase in blood pressure in the 1K-IC acquired model of hypertension remains to be determined.
Introduction
In acquired forms of hypertension, renal x-adrenoceptor density has been found to be unchanged or decreased (Yamada et al., 1980; Fukuda et al., 1983; Saiz et al., 1987; Michel et al., 1989b; Wilson, 1991) , whereas in spontaneously hypertensive rats, the density of renal a2-adrenoceptors has been found to be elevated as compared to Wistar-Kyoto rats (Pettinger et al., 1982; Saiz et al., 1987; Sanchez et al., 1989; Michel et al., 1990a) . Furthermore, previous studies in our laboratory indicated that the renal response to M2-adrenoceptor agonists such as clonidine was decreased in spontaneously hypertensive rats (Li et al., 1992) but not in one kidney, one clip (1K-IC) hypertensive rats (Li & Smyth, 1994) . The diuretic and natriuretic effects of a2-adrenoceptor stimulation have been shown to be mediated by an inhibition of the renal action of vasopressin (Blandford & Smyth, 1990; Gellai, 1990) . Thus, the decreased renal response to a V2-vasopressin receptor antagonist in spontaneously hypertensive rats but not 1K-IC hypertensive rats (Li & Smyth, 1993) was consistent with the decreased response to a2-adrenoceptor stimulation in this model of genetic hypertension.
Recent studies in our laboratory have proposed that the effects of two purported M2-adrenoceptor agonists, clonidine and 2,6-dimethyl clonidine (2,6-DMC), may in fact be mediated by two M2-adrenoceptor subtypes or two distinct receptors, a2-adrenoceptors and non-adrenoceptor, imidazoline receptors (Smyth et al., 1992a) . Whereas 2,6-DMC caused an increase in urine flow rate which was secondary to an increase in osmolar clearance, clonidine resulted in an increase in urine flow rate which was secondary to an increase in free water clearance (Smyth et al., 1992a) . Furthermore, we have recently found that the effects of 2,6-DMC but not clonidine were significantly attenuated in rats with 1K-IC hypertension (Li & Smyth, 1994) and there was a decrease in [3H]-idazoxan binding sites in kidneys from 1K-IC hypertensive rats. The ' Author for correspondence. renal actions of 2,6-DMC can be antagonized by idazoxan (Smyth & Li, 1991) which would be consistent with those effects being mediated by the non-adrenoceptor, imidazoline receptor (Feldman et al., 1990; Gomez et al., 1991; Allan et al., 1993) . Nevertheless, it has not been determined as to whether the decreased response to 2,6-DMC was due to a decreased activity at the M2-adrenoceptor or the non-adrenoceptor, imidazoline receptor.
In the present study, we determined whether or not, in 1K-IC hypertensive rats, a decreased response was found with non-adrenoceptor, imidazoline receptor agonists in general. Two agonists (rilmenidine and moxonidine) which have been shown to display a much greater selectivity and affinity for the I, non-adrenoceptor, imidazoline receptor over the a2-adrenoceptor (Ernsberger et al., 1992) , were used to investigate further the non-adrenoceptor, imidazoline receptor in 1K-IC hypertensive and 1K-sham normotensive rats.
Methods

Experimental animals
The standard procedures have been described previously (Blandford & Smyth, 1988; 1990 (Figure 1 ). Heart rate was decreased only in 1K-IC rats at the highest infusion rate of rilmenidine (30 nmol kg-' minm). Rilmenidine did not alter creatinine clearance. All doses of rilmenidine resulted in an increase in urine flow rate and sodium excretion in 1K-sham rats ( Figure  2 ). However, in 1K-IC hypertensive rats, no change in urine flow rate or sodium excretion was observed (Figure 2 ). This was reflected in significantly greater sodium excretions and urine flow rates for all doses in the 1K-sham animals. Rilmenidine increased osmolar clearance in 1K-sham normotensive rats but failed to have any effect in 1K-IC hypertensive rats (Figure 3 ). Free water clearance was not significantly altered in 1K-sham rats or 1K-IC hypertensive rats (Figure 3 ).
Effect of intrarenal infusion of moxonidine
Baseline values for experimental groups prior to the administration of the experimental treatments (vehicle, moxonidine) min-' of moxonidine were different from the group which received the saline vehicle ( Table 2 ). The differences were, a lower heart rate, increased osmolar clearance and decreased free water clearance ( Table 2) . The mean arterial blood pressure was not altered by moxonidine in either the 1K-sham normotensive rats or the 1K-1C hypertensive rats (Figure 4) . Heart rate was decreased in both 1K-sham and 1K-IC rats at the highest infusion rate of moxonidine (10 nmol kg-Imin-). Moxonidine did not alter creatinine clearance. All doses of moxonidine resulted in an increase in urine flow rate in 1K-sham rats (Figure 5) , whereas, in 1K-IC hypertensive rats, the two highest infusion rates increased urine flow rate ( Figure 5 ). The increase in urine flow rate was also greater in the 1K-sham rats as compared to the 1K-IC rats. Sodium excretion was also increased by moxonidine in 1K-sham normotensive rats at all infusion rates investigated, but only at the highest infusion rate in 1K-IC hypertensive rats ( Figure 5 ). Moxonidine increased osmolar clearance at all infusion rates investigated in 1K-sham normotensive rats but only at the highest dose in 1K-IC hypertensive rats ( Figure 6 ). Free water clearance was increased in the 1K-sham rats at the lowest and highest doses of moxonidine but not the 1K-IC hypertensive rats. Rilmenidine (nmol kg min-) Figure 3 The effects of rilmenidine on free water clearance and osmolar clearance. (Ernsberger et al., 1992; Reis et al., 1992) . A number of lines of evidence suggested that 2,6-DMC may be a non-adrenoceptor, imidazoline receptor agonist. Previous studies in our laboratory indicated that the two purported X2-adrenoceptor agonists 2,6-DMC and clonidine increased urine flow rate by two distinct mechanisms (Smyth et al., 1992a ). 2,6-DMC increased urine flow rate secondary to an increase in osmolar clearance while clonidine increased urine flow rate by increasing free water clearance. In addition, pretreatment with a V2 vasopressin antagonist had no effect on the response to 2,6-DMC but completely attenuated the effects of clonidine. These results are consistent with the effects of 2,6-DMC and clonidine being mediated by two distinct mechanisms and/or sites, a2-adrenoceptors and nonadrenoceptor, imidazoline receptors (Smyth et al., 1992a) . Effects similar to those reported with 2,6-DMC have been found by Allan et al. (1993) using moxonidine, an I, nonadrenoceptor, imidazoline receptor agonist with an approximately 700 times higher affinity for I, non-adrenoceptor, imidazoline receptors than that for x2-adrenoceptors in the kidney (Ernsberger et al., 1993) . They found that moxonidine produced an increased urine flow rate in Sprague-Dawley rats and this increase was secondary to an increase in osmolar clearance. This increase was blocked by pretreatment with idazoxan (non-adrenoceptor, imidazoline receptor antagonist) but not by pretreatment with rauwolscine (M2-adrenoceptor antagonist). The renal effects of 2,6-DMC were also blocked by idazoxan but not rauwolscine (Smyth & Li, 1991) , indicating that 2,6-DMC and moxonidine may be acting at the same site and/or receptor.
Rilmenidine has at least a 3 fold greater affinity for Ii non-adrenoceptor, imidazoline receptors than for x2-adrenoceptors (Gomez et al., 1991; Ernsberger et al., 1992) and the cardiovascular action of central administration of rilmenidine was blocked by idazoxan (Feldman et al., 1990 ). The present study demonstrated that, like moxonidine (Allan et al., 1993) and 2,6-DMC (Smyth et al., 1992a) , rilmenidine increased urine flow rate and sodium excretion in a dose-related fashion. Similarly, the increase in flow rate was associated Moxonidine (nmol kg -1 min -1) Figure 4 The effects of moxonidine on mean arterial blood pressure, heart rate and creatinine clearance. with an increase in osmolar clearance rather than an increase in free water clearance as has been documented for M2-adrenoceptor agonists (Blandford & Smyth, 1990; Gellai, 1990) . This similarity of 2,6-DMC with moxonidine and rilmenidine would be consistent with 2,6-DMC acting at the same site, i.e. the non-adrenoceptor, imidazoline receptor. However, radioligand binding studies will be required to support this contention.
In the present study, the renal effects of rilmenidine and moxonidine were significantly attenuated in 1K-IC hypertensive rats as compared with 1K-sham normotensive rats. These results were similar to those found for 2,6-DMC in 1K-IC hypertensive rats (Li & Smyth, 1994) . It is important Moxonidine (nmol kg-1 min -1) Figure 5 The effects of moxonidine on urine flow rate and sodium excretion. to note that this decrease in response to non-adrenoceptor, imidazoline agonists may be specific since the natriuretic response to an a2-adrenoceptor agonist (Li & Smyth, 1994) and a V2 vasopressin receptor antagonist (Li & Smyth, 1993) were not found to be altered in 1K-IC hypertension. During the chronic phase of 1K-IC hypertension, blood pressure is maintained by an excess of water and sodium retention (Zandberg, 1984; Nabel et al., 1985) . Conceivably, the attenuated effects of renal imidazoline receptor stimulation in lK-lC hypertensive rats could contribute to the sodium and water retention and may be caused by one of two factors. First, an increase in the endogenous levels of the non-adrenoceptor, imidazoline receptor agonist could result in a decrease in the number of these receptors available (receptor occupation) which would decrease the response to the exogenous non-adrenoceptor, imidazoline receptor agonists. At present, the endogenous agonist for non-adrenoceptor, imidazoline receptors has not been determined. However, recent studies suggest that clonidine-displacing substance may be the endogenous non-adrenoceptor, imidazoline receptor agonist (Atlas, 1991; Regunathan et al., 1991) . Second, this decreased response may represent a decrease in receptor activity. Insel & Motulsky (1988) found that M2-adrenoceptors in tissues such as those in rat kidney may be downor up-regulated. Antagonists induced an up-regulation and agonists mediated a down-regulation of x2-adrenoceptors in spontaneously hypertensive rats, DOCA-salt hypertensive rats and New Zealand Genetically Hypertensive rats (Saiz et al., 1987; Sanchez et al., 1989; Smyth et al., 1992b) . The I1 non-adrenoceptor, imidazoline receptor may also undergo similar regulation. An infusion of angiotensin II produced an up-regulation of I, sites . Similarly, although the receptor subtype was not described, Olmos et al. (1992) demonstrated that chronic treatment with idazoxan or cirazoline (imidazoline compounds) increased the density of non-adrenoceptor, imidazoline receptors in the brain of Wistar Kyoto and Sprague-Dawley rats but not spontaneously hypertensive rats. The altered non-adrenoceptor, imidazoline receptor number/activity may be secondary to increased agonist levels (clonidine-displacing substance) or a pathophysiological decrease in receptor activity. Recent studies in our laboratory have shown that [3H]-idazoxan binding was decreased in kidneys of lK-lC hypertensive rats compared with 1K-sham normotensive rats. Conversely [3H]-rauwolscine binding was similar in lK-lC hypertensive and 1K-sham normotensive rats (Li & Smyth, 1994) . This decrease in sites labelled by [3H]-idazoxan in 1K-IC kidneys would be consistent with the decrease in response to nonadrenoceptor, imidazoline agonists reported in the present study. In summary, the renal effects of rilmenidine were completely attenuated and the renal response of moxonidine was significantly decreased in lK-lC hypertensive rats compared with the response in 1K-sham normotensive rats. This attenuation indicated that the activity of renal I non-adrenoceptor, imidazoline receptors was decreased. Whether the decrease in activity of this natriuretic I, non-adrenoceptor, imidazoline receptor contributes to the increase in blood pressure in this 1K-IC acquired model of hypertension remains to be determined. 
